What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Surgery
Valerie W. Rusch mainly focuses on Lung cancer, Surgery, Adenocarcinoma, Stage and Cancer.
Valerie W. Rusch interconnects Carcinoma and Chemotherapy in the investigation of issues within Lung cancer.
Her work carried out in the field of Carcinoma brings together such families of science as Retrospective cohort study, Survival analysis and Oncology.
Her Surgery research is multidisciplinary, incorporating elements of Pneumonectomy and Extrapleural Pneumonectomy.
Her Adenocarcinoma study incorporates themes from Esophageal cancer, KRAS, Lung, Gefitinib and Esophagus.
Her Stage research integrates issues from Lymph node, Mesothelioma, Radiology and Adjuvant therapy.
Her most cited work include:
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib (3725 citations)
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (3202 citations)
- Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network (3074 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of investigation include Surgery, Internal medicine, Lung cancer, Oncology and Cancer.
Surgery connects with themes related to Pneumonectomy in her study.
Her Lung cancer study combines topics in areas such as Stage, Carcinoma, Radiology and Clinical trial.
Her study in the field of Non small cell, non-small cell lung cancer and Lung cancer staging is also linked to topics like In patient.
Her study explores the link between Pathology and topics such as Cancer research that cross with problems in Epidermal growth factor receptor.
Valerie W. Rusch combines subjects such as Esophagus and KRAS with her study of Adenocarcinoma.
She most often published in these fields:
- Surgery (36.44%)
- Internal medicine (30.17%)
- Lung cancer (28.43%)
What were the highlights of her more recent work (between 2016-2021)?
- Internal medicine (30.17%)
- Oncology (25.07%)
- Lung cancer (28.43%)
In recent papers she was focusing on the following fields of study:
Her primary areas of study are Internal medicine, Oncology, Lung cancer, Surgery and Cancer.
Her biological study spans a wide range of topics, including Prospective cohort study, Atezolizumab, Targeted therapy and Chemotherapy.
Her Lung cancer research incorporates elements of Neoadjuvant therapy, Clinical trial, Carcinoma, Radiology and Nivolumab.
Valerie W. Rusch studied Surgery and Pneumonectomy that intersect with Comorbidity.
Her Cancer study also includes
- Mutation together with Cancer research and Genetic testing,
- MEDLINE which connect with Esophagectomy.
Her research integrates issues of Disease and Adenocarcinoma in her study of Stage.
Between 2016 and 2021, her most popular works were:
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer (786 citations)
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. (269 citations)
- Integrative Molecular Characterization of Malignant Pleural Mesothelioma (232 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
Her primary areas of investigation include Internal medicine, Oncology, Lung cancer, Cancer and Surgery.
Her Oncology study integrates concerns from other disciplines, such as Chemotherapy, Carcinoma, Lung, Stage and Prospective cohort study.
Her Lung cancer research includes elements of Neoadjuvant therapy, Nivolumab, Clinical trial and Radiology.
Her Clinical trial research is multidisciplinary, incorporating elements of Adjuvant and Mesothelioma.
Her Cancer research is multidisciplinary, incorporating perspectives in Mutation and Cancer research.
Her research in Surgery intersects with topics in Metastasectomy, Adverse effect and Primary tumor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
